Walleye Capital LLC Sells 436,402 Shares of Perspective Therapeutics, Inc. $CATX

Key Points

• Walleye Capital LLC significantly reduced its investment in Perspective Therapeutics, selling 436,402 shares and decreasing its stake by 91.7%, now holding just 39,390 shares worth $84,000.
• Several other institutional investors have recently taken positions in Perspective Therapeutics, including ProShare Advisors LLC, which increased its stake by 49.1%, resulting in a combined institutional ownership of 54.66%.
• Analysts have mixed outlooks on Perspective Therapeutics, with ratings ranging from "Strong Buy" to "Hold," and a consensus target price of $12.56.

Walleye Capital LLC lessened its holdings in Perspective Therapeutics, Inc. (NYSE:CATX - Free Report) by 91.7% during the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,390 shares of the company's stock after selling 436,402 shares during the period. Walleye Capital LLC owned 0.05% of Perspective Therapeutics worth $84,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. ProShare Advisors LLC raised its position in shares of Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company's stock worth $49,000 after buying an additional 5,011 shares in the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth $51,000. Corton Capital Inc. purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth $61,000. Wexford Capital LP purchased a new stake in shares of Perspective Therapeutics in the fourth quarter worth $64,000. Finally, Sherbrooke Park Advisers LLC purchased a new stake in Perspective Therapeutics during the fourth quarter valued at about $69,000. Hedge funds and other institutional investors own 54.66% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CATX shares. Lifesci Capital upgraded Perspective Therapeutics to a "strong-buy" rating in a research report on Saturday, July 12th. Wedbush restated an "outperform" rating and set a $11.00 price target on shares of Perspective Therapeutics in a research report on Monday, June 23rd. B. Riley restated a "buy" rating and set a $12.00 price target (up previously from $9.00) on shares of Perspective Therapeutics in a research report on Monday, June 23rd. Truist Financial lowered their price target on Perspective Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a research report on Wednesday, May 14th. Finally, Royal Bank Of Canada upgraded Perspective Therapeutics from an "outperform" rating to a "moderate buy" rating and raised their price target for the company from $15.00 to $16.00 in a research report on Tuesday, June 3rd. Three research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $12.56.

Perspective Therapeutics Stock Up 4.6%

Shares of CATX traded up $0.15 during trading hours on Thursday, hitting $3.38. The company had a trading volume of 588,198 shares, compared to its average volume of 917,266. The stock's 50 day moving average price is $3.74 and its 200 day moving average price is $3.00. Perspective Therapeutics, Inc. has a 52-week low of $1.60 and a 52-week high of $16.19.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.